share_log

BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25

Moomoo 24/7 ·  Mar 12 11:11

BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and lowers the price target from $3.3 to $3.25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment